Analyst Ratings For Crispr Therapeutics AG (NASDAQ:CRSP)
Today, Needham & Company LLC initiated coverage on Crispr Therapeutics AG (NASDAQ:CRSP) with a Buy with a price target of $62.00.
There are 8 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.
The current consensus rating on Crispr Therapeutics AG (NASDAQ:CRSP) is Buy with a consensus target price of $64.6889 per share, a potential 67.07% upside.
Some recent analyst ratings include
- 11/30/2018-Crispr Therapeutics AG (NASDAQ:CRSP) has coverage initiated with a Buy rating and $62.00 price target
- 10/10/2018-Crispr Therapeutics AG (NASDAQ:CRSP) has coverage initiated with a Outperform ➝ Outperform rating and $65.00 price target
- 10/9/2018-Crispr Therapeutics AG (NASDAQ:CRSP) has coverage initiated with a Neutral ➝ Neutral rating
- 9/20/2018-Crispr Therapeutics AG (NASDAQ:CRSP) has coverage initiated with a Underperform ➝ Underperform rating
- 9/17/2018-Crispr Therapeutics AG (NASDAQ:CRSP) had its Hold rating reiterated by Cann
- 8/8/2018-Crispr Therapeutics AG (NASDAQ:CRSP) had its Buy rating reiterated by Chardan Capital with a $72.50 price target
- On 7/5/2018 Pablo J Cagnoni, Director, sold 7,500 with an average share price of $62.00 per share and the total transaction amounting to $465,000.00.
- On 7/3/2018 Pablo J Cagnoni, Director, sold 5,816 with an average share price of $62.00 per share and the total transaction amounting to $360,592.00.
- On 6/5/2018 Kurt Von Emster, Director, sold 920 with an average share price of $12.51 per share and the total transaction amounting to $11,509.20.
- On 6/1/2018 Samarth Kulkarni, CEO, sold 15,000 with an average share price of $69.36 per share and the total transaction amounting to $1,040,400.00.
- On 5/17/2018 Rodger Novak, President, sold 75,000 with an average share price of $60.00 per share and the total transaction amounting to $4,500,000.00.
- On 5/14/2018 Kurt Von Emster, Director, sold 650,000 with an average share price of $54.39 per share and the total transaction amounting to $35,353,500.00.
- On 5/11/2018 Kurt Von Emster, Director, sold 250,000 with an average share price of $52.84 per share and the total transaction amounting to $13,210,000.00.
About Crispr Therapeutics AG (NASDAQ:CRSP)
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient. The company is also developing CTX101, a donor-derived gene-edited allogeneic CAR-T therapy targeting CD19-positive malignancies. In addition, it is developing earlier stage allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; hemoglobinopathies to treat other diseases, including Hurler Syndrome and severe combined immunodeficiency disease; programs that are in preclinical development for indications, including glycogen storage disease Ia and hemophilia; and programs targeting diseases of organ systems outside the liver, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use therapeutics. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer; and with the ViaCyte, Inc. for designing allogeneic cell therapies derived from gene edited human stem cells for use in the treatment of diabetes type 1, diabetes type 2, and insulin dependent diabetes. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Recent Trading Activity for Crispr Therapeutics AG (NASDAQ:CRSP)
Shares of Crispr Therapeutics AG closed the previous trading session at 38,72 up +1,10 2,92 % with 39.2 shares trading hands.